DCN1-IN-2, with the CAS number 2543578-57-8, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential as a therapeutic agent. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. This compound is often studied for its role as an inhibitor in certain biochemical pathways, making it a candidate for drug development, especially in the context of cancer research. The compound's solubility, stability, and interaction with biological targets are critical characteristics that influence its efficacy and safety profile. Additionally, DCN1-IN-2 may exhibit unique pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), which are essential for understanding its behavior in biological systems. As research progresses, further insights into its mechanism of action and potential therapeutic applications are anticipated, highlighting the importance of ongoing studies in the field of drug discovery.

DCN1-IN-2

2543578-57-8: DCN1-IN-2, with the CAS number 2543578-57-8, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential as a therapeutic agent. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. This compound is often studied for its role as an inhibitor in certain biochemical pathways, making it a candidate for drug development, especially in the context of cancer research. The compound's solubility, stability, and interaction with biological targets are critical characteristics that influence its efficacy and safety profile. Additionally, DCN1-IN-2 may exhibit unique pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), which are essential for understanding its behavior in biological systems. As research progresses, further insights into its mechanism of action and potential therapeutic applications are anticipated, highlighting the importance of ongoing studies in the field of drug discovery.

<p>DCN1-IN-2, a DCN1 inhibitor, exhibits potent activity with an IC 50 of 2.96 nM. It effectively mitigates Ang II/TGFβ-induced activation of cardiac fibroblasts and diminishes ISO-induced cardiac fibrosis and remodeling in mice through the selective inhibition of cullin 3.</p>

CAS 2543578-57-8

DCN1-IN-2

DCN1-IN-2

Ref: TM-T89956